Notes to the Financial Statements For the Year Ended 30 June 2026 Contents About this Report 92 Notes to the financial statements: 92 Our Current Performance 94 Note 1: Segment Information 94 Note 2: Revenue and Expenses 97 Note 3: Restructuring and Impairment Expenses 99 Note 4: Tax 104 Note 5: Inventories 106 Note 6: People Costs 107 Our Future 109 Note 7: Research and Development Activities 109 Note 8: Intangible Assets 109 Note 9: Property, Plant and Equipment 111 Returns, Risk & Capital Management 112 Note 10: Shareholder Returns 112 Note 11: Financial Risk Management 113 Note 12: Equity and Reserves 119 Note 13: Commitments and Contingencies 120 Efficiency of Operation 121 Note 14: Receivables, Contract Assets and Payables 121 Note 15: Provisions 122 Other Notes 123 Note 16: Related Party Transactions 123 Note 17: Detailed Information - People Costs 124 Note 18: Auditor Remuneration 128 Note 19: Deed of Cross Guarantee 129 Note 20: Parent Entity Information 131 Note 21: Non-Controlling Interests 131 Note 22: Subsequent Events 132 Note 23: Amendments to Accounting Standards and Interpretations 132 About this Report Notes to the financial statements: Corporate information CSL Limited (CSL) is a for-profit company incorporated and domiciled in Australia and limited by shares publicly traded on the Australian Securities Exchange. This financial report covers the financial statements for the consolidated entity consisting of CSL and its subsidiaries (together referred to as the Group). The financial report was authorised for issue in accordance with a resolution of directors on 17 August 2026. A description of the nature of the Group’s operations and its principal activities is included in the directors’ report. a. Basis of preparation This general purpose financial report has been prepared in accordance with Australian Accounting Standards, other authoritative pronouncements of the Australian Accounting Standards Board (AASB), International Financial Reporting Standards (IFRS) and the Corporations Act 2001. It presents information on a historical cost basis, except for certain financial instruments, which have been measured at fair value. Amounts have been rounded off to the nearest million dollars. The report is presented in US dollars, because this currency is the pharmaceutical industry standard currency for reporting purposes. It is also the predominant currency of the Group’s worldwide sales and operating expenses. b. Principles of consolidation The financial report comprises the financial statements of CSL and its subsidiaries as at 30 June 2026. CSL has control of its subsidiaries when it is exposed to, and has the rights to, variable returns from its involvement with those entities and when it has the ability to affect those returns. A list of significant controlled entities (subsidiaries) at year end is contained in Note 16. Where the Group's interest in a subsidiary is less than 100%, the interest attributable to outside shareholders is reflected in non-controlling interest. Non-controlling interests in the financial results and equity of subsidiaries are shown separately in the consolidated statement of comprehensive income, statement of changes in equity and balance sheet respectively. Further details about the Group's non-controlling interest is contained in Note 21. The financial results of the Group's subsidiaries are prepared using consistent accounting policies and for the same reporting period as the parent company. In preparing this financial report, all intercompany balances and transactions have been eliminated in full. The Group has formed a trust, CSL Employee Share Trust, to administer the Group’s employee share plan (GESP). This trust is consolidated as it is controlled by the Group. 92 For the Year Ended 30 June 2026 92 Financial Report
RkJQdWJsaXNoZXIy MjE2NDg3